Our therapeutics are produced and secreted in the gut using genetically engineered probiotics. This allows us to target pathogens entrenched deep inside the biofilms.
We leverage narrow spectrum antimicrobial peptides that do not harm the beneficial microbes and promote a healthy intestinal environment.
Microbiome plays an important role in your health. Research shows that when microbial balance is disrupted, pathogenic microbes take hold and can cause or promote a range of chronic diseases. Gutbiotics is currently focused on disorders where the causal link with microbes has been well established. These include:
Over 2 million Americans suffer from IBD which includes Crohn’s disease and Ulcerative colitis. These patients experience debilitating digestive symptoms like persistent diarrhea, rectal bleeding, and abdominal pain resulting in a detrimental impact on quality of life.
Over 12 million Americans suffering from irritable bowel syndrome (IBS) have an underlying condition of small intestinal bacterial overgrowth (SIBO)
The available therapeutic options have several limitations for precisely manipulating and fine tuning the microbiome.
have a broad-spectrum action and disrupt the entire microbiome by killing the beneficial bacteria. Moreover 55 -70% of the implicated pathogens isolated from IBD patients were found to be multi drug resistant.
The generally regarded as safe probiotic strains do not have the capability to decolonize pathogenic strains like Escherichia coli and Klebsiella pneumonia.
have a high specificity to a target pathogenic strain and therefore require an accurate identification of the problematic bacteria for selecting appropriate phage.
Genetically engineered probiotics are a novel class of medicine and offer several advantages compared to antibiotics, probiotics, and bacteriophages.
Our engineered probiotics produce and secrete antimicrobial peptides that are potent against the multi-drug resistant bacteria and pathogens have a significantly low probability of developing resistance against these peptides.
The use of probiotic bacteria to deliver therapeutics is more effective because bacteria can reach places that orally ingested therapeutics can not. Genetically modified bacteria can penetrate biofilms and reach deep inside gut mucosa thereby ensuring target pathogens are eliminated.
Our narrow spectrum peptides selectively reduce pathogenic species of bacteria and leave the native microbiome intact. Further the engineered probiotic strains promote a healthy intestinal environment.
https://www.thegutbiotics.com/wp-content/uploads/2022/12/SIBO_Pathogens_595.png
307
595
Sumit Khetarpal
https://www.thegutbiotics.com/wp-content/uploads/2023/06/340x156-pixels-01.png
Sumit Khetarpal2022-12-01 05:30:132023-07-26 05:01:46Pathogens Behind SIBO And Limitations of Rifaximin
https://www.thegutbiotics.com/wp-content/uploads/2022/09/lab_scientistC.jpg
396
595
Sumit Khetarpal
https://www.thegutbiotics.com/wp-content/uploads/2023/06/340x156-pixels-01.png
Sumit Khetarpal2022-09-21 13:01:162022-12-01 05:25:55Principal Scientist – Strain Engineering
https://www.thegutbiotics.com/wp-content/uploads/2022/01/Ineffective_Antibiotics.jpg
341
592
Sumit Khetarpal
https://www.thegutbiotics.com/wp-content/uploads/2023/06/340x156-pixels-01.png
Sumit Khetarpal2022-01-10 03:14:402022-12-01 05:26:38A Tale Of Ineffective Antibiotics – Meet A SIBO Warrior Abigail Dancause
https://www.thegutbiotics.com/wp-content/uploads/2021/12/Antimicrobial_Peptides_595.jpg
265
595
Sumit Khetarpal
https://www.thegutbiotics.com/wp-content/uploads/2023/06/340x156-pixels-01.png
Sumit Khetarpal2021-12-31 22:51:112022-12-01 05:26:55The Future of Anti-Microbials For SIBO – A Discussion With Dr. Bryan Davies